Citius Pharmaceuticals and Citius Oncology to launch Lymphir in 1H25

Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR), announced progress in preparations for the commercial launch of Lymphir, an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. Management is focused on making Lymphir available to patients as quickly as possible, with preparations underway for launch in the first half of 2025. “Since Lymphir’s approval in August 2024, we have worked diligently toward supporting its successful launch. We are making significant progress to finalize our manufacturing, marketing, reimbursement and sales efforts. This is a pivotal inflection point as we transition from clinical development to revenue generation. Our strategy not only focuses on a successful U.S. market penetration, but also includes exploring additional growth opportunities, including licensing partnerships in key international markets, for which discussions are underway, expanded indications for Lymphir, in addition to Lymphir’s potential as a combination immunotherapy,” stated CEO Leonard Mazur. Lymphir was approved by the FDA in August 2024.